Afamitresgene autoleucel as an effective T-cell therapy for synovial sarcoma and liposarcoma
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events...
Read MoreMay 2, 2024
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events...
Read MoreMay 1, 2024
1. Progression-free survival at 24 months was higher in the pembrolizumab versus...
Read MoreApr 30, 2024
1. For patients with localized endometrial cancer recurrence, adding cisplatin to radiation...
Read MoreApr 30, 2024
1. The median overall survival was 17.6 months in the gefitinib group vs 27.5 months in the...
Read MoreApr 25, 2024
1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion...
Read MoreApr 25, 2024
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo...
Read MoreApr 23, 2024
1. Mitoxantrone enhances five-year event-free survival over liposomal daunorubicin in MRD-guided...
Read MoreApr 19, 2024
BIO 300 use led to reduced levels of a proinflammatory/profibrotic cytokine associated with lung...
Read MoreApr 16, 2024
1. When compared to upfront surgery, neoadjuvant chemotherapy using mFOLFOX or CAPOX did not...
Read MoreApr 16, 2024
1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion...
Read MoreApr 9, 2024
1. Roughly 65% of the cancer medication budget is allocated to treatments that provide improvement...
Read MoreApr 9, 2024
1. The pathological response rate had an OR of 3.16 when comparing neoadjuvant dual vs single...
Read MoreApr 3, 2024
1. 18-month recurrence-free survival was significantly greater in the combination therapy group...
Read MoreApr 2, 2024
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma...
Read MoreApr 2, 2024
1. The overall survival had a significant hazard ratio (0.65) when comparing neoadjuvant...
Read MoreMar 26, 2024
1. Invasive disease-free survival was significantly higher in patients receiving adjuvant...
Read MoreMar 26, 2024
1. VENICE-1 observed high response rates (complete or partial remission) in both BCRi-naïve and...
Read MoreMar 26, 2024
1. 83.1% of patients with confirmed colorectal cancer had a positive cfDNA test meeting the...
Read MoreMar 26, 2024
1. Adding chemotherapy to immunotherapy did not prolong OS or PFS, with non-significant...
Read MoreMar 23, 2024
1. There were similar rates of ipsilateral invasive recurrence among the postoperative adjuvant...
Read More